TrialCardiovascular diabetology2025

Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.

Litong Qi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.